EsoBiotec’s proprietary ENaBL platform redefines adoptive cell therapy, enabling single IV, off-the-shelf treatments that reduce costs, improve patient experience, ...

EsoBiotec Chief Scientific Officer Philippe Parone, Ph.D., commented, “ESO-T01 leverages our third-generation immune-shielded lentiviral vector platform, ENaBL, designed to reprogram T cells ...

British drug major AstraZeneca said on Monday it has entered into a definitive agreement to acquire EsoBiotec, a Belgian biotech company, for up to $1 billion on a cash and debt-free basis. The ...

AstraZeneca, the British and Swedish joint venture pharmaceutical and biotech company, announced that it has reached an agreement to acquire EsoBiotec, according to a press release by the company ...

EsoBiotec ready to transform cell therapy cancer treatments · EsoBiotec, a recently founded biotech company, announces a EUR 6 million pre-series A round comprised of non-dilutive funding from the ...

EsoBiotec's proprietary ENaBL platform redefines adoptive cell therapy, enabling single IV, off-the-shelf treatments that reduce costs, improve patient experience, ...

EsoBiotec's pipeline features two first-in-class, combination candidates-ESO-TX101 and ESO-TX102-designed to build on the simultaneous engineering of T cells and monocytes to remodel the tumor ...

EsoBiotec investors include Thuja Capital, UCB Ventures, Invivo Partners, Wallonie Entreprendre (WE), SambrInvest and Investsud. EsoBiotec’s proprietary ENaBL platform redefines adoptive cell ...

EsoBiotec. Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapy. MONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec ...